BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright cut their target price on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, November 25th.

BioLineRx Trading Up 3.5 %

BLRX opened at $0.30 on Monday. The stock has a market capitalization of $23.74 million, a price-to-earnings ratio of -1.35 and a beta of 1.48. The company has a quick ratio of 1.49, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. BioLineRx has a twelve month low of $0.25 and a twelve month high of $1.89. The company has a 50-day simple moving average of $0.45 and a 200 day simple moving average of $0.60.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BLRX. PVG Asset Management Corp bought a new stake in shares of BioLineRx during the 2nd quarter valued at approximately $70,000. CVI Holdings LLC acquired a new stake in BioLineRx in the second quarter valued at approximately $462,000. Finally, Atria Investments Inc grew its stake in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares during the last quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.